What is the relationship between cycloserine and dastrazeneca

Cycloserine (Cycloserine) is a prescription drug belonging to the antibiotic drug family. It is mainly used to treat pulmonarytuberculosis, especially in patients with drug-resistant tuberculosis or in whom conventional treatments are ineffective. DastraZeneca is the trade name of cycloserine's generic drug marketed in China. The relationship between the two is equivalent to the relationship between "generic name and trade name". In other words, cycloserine is the internationally accepted name of the drug, while datraZeneca is the trade name adopted by the manufacturer to facilitate marketing and prescription circulation.

From a pharmacological point of view, whether they are original drugs or generic drugs, their active ingredient is cycloserine. The same raw material medicine means that there is no essential difference in the mechanism of action, indications and usage. However, different manufacturers may have differences in preparation technology, excipient selection and quality control, so there will be certain differences in drug absorption rate, tolerance and price. Generally speaking, generic drugs must undergo verification of bioequivalence, which means that their efficacy and safety should be consistent with the original drug.

In the field of tuberculosis treatment, cycloserine is usually not used alone, but in combination with other anti-tuberculosis drugs to reduce the risk of drug resistance and improve efficacy. The launch of DastraZeneca in China has improved the accessibility of cycloserine and provided patients with more treatment options. With the increase in drug-resistant tuberculosis cases, the importance of cycloserine has gradually come to the fore, especially in the treatment of multidrug-resistant or extensively drug-resistant tuberculosis, and it is still recommended by international guidelines as one of the second-line drugs.

Therefore, The relationship between cycloserine and DastraZeneca is similar to the corresponding relationship between "pharmaceutical name and brand name". When prescribing, clinicians may choose brand-name drugs based on the patient's condition, drug availability, and medical insurance reimbursement policies. Patients only need to make sure that the active ingredient is cycloserine when using it, and there is no need to worry about differences in efficacy due to different brands.

Reference materials:https://en.wikipedia.org/wiki/Cycloserine